Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes

Endocrine
Inmaculada PeiróCarlos Villabona

Abstract

Nivolumab is a monoclonal antibody that blocks the activation of programmed death-1 receptor, promoting T-cell activation against cancer cells. Thyroid dysfunction (TD) is a common immune-related adverse event (irAE) induced by nivolumab. We report the prevalence, patterns and outcomes of nivolumab-induced TD among cancer patients in our center. All patients treated with nivolumab during 2016 were included. We assessed thyroid function tests, thyroid autoimmunity, thyroid imaging, and clinical outcome during nivolumab therapy as well as overall survival (OS). Seventy-three patients (55 with non-small-cell lung cancer [NSCLC], 9 with melanoma and 9 with Hodgkin lymphoma) were included. Median of follow up: 390.5 days. Seventeen patients (23.3%) developed TD during treatment. Thyrotoxicosis was reported in seven patients. Serum thyroid-stimulating hormone (TSH) nadir occurred after a median of 51 days (95% CI: 35-71). Thyroid antibodies were positive in three of the seven patients. Five of the seven hyperthyroid patients became hypothyroid later, and four of them required levothyroxine treatment. Primary hypothyroidism occurred in ten patients. Serum TSH peak occurred after a median of 110 days [95% CI: 85.2-197]. Thyroid autoimm...Continue Reading

References

Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yoshiko IwaiNagahiro Minato
Dec 7, 2007·American Journal of Epidemiology·Samy Suissa
Mar 17, 2010·BMJ : British Medical Journal·Linda E LévesqueSamy Suissa
Aug 1, 2014·The Journal of Clinical Endocrinology and Metabolism·Alexander T FajeLisa Nachtigall
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Mar 10, 2015·The Journal of Clinical Endocrinology and Metabolism·Steven OrlovPaul G Walfish
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Jul 13, 2016·The Oncologist·Jeffrey S WeberDirk Schadendorf
Nov 5, 2016·The Journal of Clinical Endocrinology and Metabolism·Jeroen de FiletteBert Bravenboer
May 26, 2017·Thyroid : Official Journal of the American Thyroid Association·Ichiro YamauchiNobuya Inagaki
Aug 23, 2017·European Journal of Internal Medicine·Pedro Iglesias
Oct 14, 2017·Endocrine-related Cancer·Priscilla CukierAna O Hoff
Nov 23, 2017·Journal for Immunotherapy of Cancer·I PuzanovUNKNOWN Society for Immunotherapy of Cancer Toxicity Management Working Group
Dec 15, 2017·Journal of Endocrinological Investigation·P ChalanP Caturegli
Feb 15, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerUNKNOWN National Comprehensive Cancer Network
Feb 28, 2018·Hematological Oncology·Salvatrice MancusoSergio Siragusa
Mar 28, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philippe ArmandStephen M Ansell
Mar 31, 2018·Journal of the Endocrine Society·Tomoko KobayashiHiroshi Arima
Nov 22, 2018·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Koichi SatoNobuyuki Yamamoto
Jul 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J B A G HaanenUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

❮ Previous
Next ❯

Citations

Aug 31, 2019·BMJ Case Reports·Catarina Martins MachadoMaria João Oliveira
Apr 30, 2020·Immunotherapy·Maria V DeligiorgiDimitrios T Trafalis
Jul 28, 2020·Cancer Immunology, Immunotherapy : CII·Joana Lima FerreiraIsabel Torres
Apr 9, 2020·Thyroid : Official Journal of the American Thyroid Association·Christopher A MuirVenessa H M Tsang
Aug 12, 2020·Clinical Lymphoma, Myeloma & Leukemia·Shravya R GinnaramNishitha M Reddy
Dec 29, 2020·Journal of Endocrinological Investigation·L BrilliM G Castagna
Mar 2, 2021·Seminars in Ophthalmology·Loulwah Mukharesh, Bart K Chwalisz
Oct 17, 2020·Endocrinología, Diabetes Y Nutrición·Enzamaria FidilioCarles Zafón
Jul 17, 2021·Current Opinion in Endocrinology, Diabetes, and Obesity·Anupam Kotwal, Mabel Ryder
Jan 14, 2022·Cancer Immunology, Immunotherapy : CII·Yee-Ming Melody CheungOle-Petter Riksfjord Hamnvik

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Thyroiditis

Autoimmune thyroiditis is an inflammatory disease of thyroid gland due to autoimmune responses leading to lymphocytic infiltration of the gland. It is characterized by the presence of circulating thyroid antigen-specific T-cells and thyroid autoantibodies. Discover the latest research on autoimmune thyroiditis here.